Athira Pharma(ATHA) - 2025 Q3 - Quarterly Results

Exhibit 99.1 Athira Pharma Reports Third Quarter 2025 Financial Results and Provides Business Update • Athira conducted the first-in-human Phase 1 (NCT 06432647) double-blind, placebo- controlled clinical trial that enrolled 80 healthy volunteers to evaluate single and multiple oral ascending doses of ATH-1105. The study was completed in November 2024 and evaluated the safety and tolerability of ATH-1105 and included measurements of pharmacokinetic outcomes. Corporate Updates Financial Results Continuing to ...